1. Infectious Diseases Society of America (2012) Infectious Diseases Society of America’s (IDSA) statement promoting anti-infective development and antimicrobial stewardship through the U.S. Food and Drug Administration Prescription Drug User Fee Act (PDUFA) reauthorization before the House Committee on Energy and Commerce Subcommittee on Health, 8 Mar 2012.
http://www.idsociety.org/uploadedfiles/idsa/policy_and_advocacy/current_topics_and_issues/advancing_product_research_and_development/bad_bugs_no_drugs/statements/idsa%20pdufa%20gain%20testimony%20030812%20final.pdf
2. Infectious Diseases Society of America (2010) The 10 x ’20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 50:1081–1083
3. Boucher HW, Talbot GH, Bradley JS et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1–12
4. Nordberg, P., Monnet, D.L., Cars, O. (2005) Priority medicines for Europe and the world: a public health approach to innovation. Antibacterial drug resistance. Background document for the WHO project. World Health Organization.
http://apps.who.int/medicinedocs/en/m/abstract/Js16368e/
5. Nathan C, Goldberg FM (2005) Outlook: the profit problem in antibiotic R&D. Nat Rev Drug Discov 4:887–891